C. Borel

L. Obéric, L. Ysebaert, C. Laurent, 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Prognostic impact of viral reactivations in acute myeloid leukemia patients undergoing allogeneic stem cell transplantation in first complete response

C. Mengelle, C. Récher, M. Attal, 2016, Medicine.

PET-Based Response after 2 Cycles of Brentuximab Vedotin in Combination with AVD for First-Line Treatment of Unfavorable Early-Stage Hodgkin Lymphoma: First Analysis of the Primary Endpoint of Breach, a Randomized Phase II Trial of Lysa-FIL-EORTC Intergroup

A. Stamatoullas, M. Federico, L. Specht, 2017 .

Extracorporeal Photopheresis: An Efficacious and Well-Tolerated Treatment for Cutaneous and Oral Mucosal Chronic Graft-versus-Host Disease

M. Marguery, C. Paul, C. Dimeglio, 2018, Dermatology.

Breast cancer in patients treated for Hodgkin's disease: clinical and pathological analysis of 76 cases in 63 patients.

R. Arriagada, F. Dhermain, J. Tortochaux, 1997, European journal of cancer.

Intensive concomitant chemoradiotherapy in locally advanced unresectable squamous cell carcinoma of the head and neck: a phase II study of radiotherapy with cisplatin and 7-week continuous infusional fluorouracil.

J. Armand, F. Eschwège, F. Janot, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study

A. Stamatoullas, P. Feugier, M. André, 2022, Leukemia & lymphoma.

Prospective Phase II Study of Prophylactic Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome

P. Chevallier, I. Yakoub-Agha, M. Mohty, 2016 .

Efficacy of minimal residual disease driven immune-intervention after allogeneic hematopoietic stem cell transplantation for high-risk chronic lymphocytic leukemia: results of a prospective multicenter trial

P. Chevallier, G. Guillerm, J. Bay, 2020, Haematologica.

[National patient follow-up care logbook: Guidelines by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

I. Yakoub-Agha, N. Chevallier, L. Magro, 2016, Bulletin du cancer.

Photo‐induced graft‐versus‐host disease

C. Pauwels, M. Marguery, C. Paul, 2016, Photodermatology, photoimmunology & photomedicine.

Initial absolute lymphocyte count as a prognostic factor for outcome in acute myeloid leukemia

C. Dumontet, X. Thomas, M. Elhamri, 2014, Leukemia & lymphoma.

Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia

G. Laurent, L. Obéric, L. Ysebaert, 2013, Haematologica.

Nivolumab in refractory cerebral relapse of Hodgkin’s lymphoma

L. Obéric, L. Ysebaert, C. Laurent, 2021, Leukemia & lymphoma.

Efficacy of chemotherapy or chemo‐anti‐PD‐1 combination after failed anti‐PD‐1 therapy for relapsed and refractory hodgkin lymphoma: A series from lysa centers

L. Obéric, L. Ysebaert, T. Filleron, 2018, American journal of hematology.

[How to handle unexpected biological abnormalities observed in the pre-donation workup for hematopoietic stem cell transplantation: an SFGM-TC report on pre-transplant cytomegalovirus, Epstein-Barr virus, Toxoplasma gondii, or syphilis IgM positive serology test].

I. Yakoub-Agha, A. Thiébaut, N. Milpied, 2013, Pathologie-biologie.

Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients.

T. Petit, V. Diéras, P. Kerbrat, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy.

T. Petit, R. Millon, J. Rodier, 2004, European journal of cancer.

Fotemustine (S 10036) in the Intra‐Arterial Treatment of Liver Metastasis from Malignant Melanoma: A Phase II Study

C. Jacquillat, G. Auclerc, D. Khayat, 1991, American journal of clinical oncology.

Oral acute graft versus host disease after donor lymphocyte infusions: Clinicopathological characterization in a monocenter cohort.

C. Récher, V. Sibaud, N. Gomes, 2020, Oral oncology.

Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome

M. Labopin, P. Chevallier, I. Yakoub-Agha, 2019, Bone Marrow Transplantation.

Phase I study of Datelliptium chloride, hydrochloride given by 24-h continuous intravenous infusion

M. Weil, D. Khayat, M. Azab, 2004, Cancer Chemotherapy and Pharmacology.

Dose-finding study of oral idarubicin and cyclophosphamide in first-line treatment of elderly patients with metastatic breast cancer.

G. Deplanque, J. Bergerat, P. Dufour, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Bronchoscopic treatment of endobronchial inflammatory myofibroblastic tumors.

J. Mazières, N. Guibert, C. Hermant, 2020, The Annals of thoracic surgery.

Improved outcome for AML patients over the years 2000–2014

G. Laurent, C. Récher, I. Luquet, 2017, Blood Cancer Journal.

Improved outcome for AML patients over the years 2000–2014

G. Laurent, C. Récher, I. Luquet, 2017, Blood Cancer Journal.

Changes on chest HRCT in systemic sclerosis-related interstitial lung disease after autologous haematopoietic stem cell transplantation

D. Farge, P. Otal, M. Resche-Rigon, 2022, Rheumatology.

Uterine chloroma, aortic thrombus and CALM/AF10 acute myeloid leukemia.

C. Récher, C. Demur, X. Chaufour, 2010, Leukemia research.

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.

M. Vekemans, P. Moreau, H. Avet-Loiseau, 2022, Blood.

Systematic esophageal endoscopy screening in patients previously treated for head and neck squamous-cell carcinoma.

S. Schraub, T. Petit, C. Borel, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Paraneoplastic temporal lobe epilepsy and anti-Yo autoantibody.

T. Petit, J. Janser, C. Borel, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics

J. Blay, J. Bonneterre, I. Ray-Coquard, 2010, Investigational New Drugs.

Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5‐year analysis of the French early access program (EPA)

R. Houot, A. Stamatoullas, O. Casasnovas, 2022, British Journal of Haematology.

Pooled Allogenic Fecal Microbiotherapy MaaT013 for the Treatment of Steroid-Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Phase IIa Heracles Study and Expanded Access Program

H. Lanic, P. Chevallier, M. Mohty, 2021, Blood.

Bortezomib and High-Dose Melphalan Vs. High-Dose Melphalan As Conditioning Regimen before Autologous Stem Cell Transplantation in De Novo Multiple Myeloma Patients: A Phase 3 Study of the Intergroupe Francophone Du Myelome (IFM 2014-02)

B. Pégourié, P. Moreau, M. Macro, 2017 .

[Palliative care in hematopoietic stem-cell transplanted patients: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

I. Yakoub-Agha, V. Coiteux, J. Bonneau, 2021, Bulletin du cancer.

[Management of CAR-T cell-related encephalopathy syndrome in adult and pediatric patients: Recommendations of the French Society of Bone Marrow transplantation and cellular Therapy (SFGM-TC)].

A. Baruchel, I. Yakoub-Agha, A. Moreau, 2019, Bulletin du cancer.

Efficacy of Chemotherapy or Chemo-Anti-PD-1 Combination after Unsatisfactory Response of Anti-PD-1 Therapy for Relapsed and Refractory Hodgkin Lymphoma: A Retrospective Series from Lysa Centers

L. Obéric, L. Ysebaert, T. Filleron, 2017 .

A longitudinal study of non-medical determinants of adherence to R-CHOP therapy for diffuse large B-cell lymphoma: implication for survival

C. Delpierre, G. Laurent, C. Récher, 2015, BMC Cancer.

Prognostic Impact of Mutations in the Nucleophosmin (NPM1) and of the FMS-Related Tyrosine Kinase 3 (FLT3) Genes in Elderly Patients with Acute Myeloid Leukemia (AML) Treated with Intensive Chemotherapy

S. Olschwang, C. Récher, C. Demur, 2008 .

Brentuximab vedotin and bendamustine as first-line treatment of Hodgkin lymphoma in the elderly (HALO Trial).

A. Rossi, R. Schiappa, A. Gallamini, 2020 .

Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma.

C. Borel, L. Thill, D. Khayat, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.

M. Ychou, J. Duffour, M. Ducreux, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Epidemiology and First-Line Treatment in Immune Thrombocytopenia Adults. Results of the Carmen Prospective Cohort

M. Lapeyre-Mestre, G. Martin-Blondel, G. Moulis, 2015 .

[Management of CAR-T cell-related encephalopathy syndrome in adult and pediatric patients: Recommendations of the French Society of Bone Marrow transplantation and cellular Therapy (SFGM-TC)].

A. Baruchel, I. Yakoub-Agha, A. Moreau, 2020, Bulletin du cancer.

Successful and Safe Treatment of Intestinal Graft-Versus-Host Disease (GvHD) with Pooled-Donor Full Ecosystem Microbiota Biotherapeutic: Results from a 29 Patient-Cohort of a Compassionate Use/Expanded Access Treatment Program

M. Mohty, R. Devillier, J. Cornillon, 2020 .

Higher doses of alpha-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma.

J. Armand, P. Soulié, L. Trandafir, 1997, European journal of cancer.